
1. biotechnol lett. 2017 sep;39(9):1375-1380. doi: 10.1007/s10529-017-2372-8. epub
2017 jun 13.

application recombinant hemagglutinin proteins alternative antigen
standards pandemic influenza vaccines.

choi y(1)(2), kwon sy(1), oh hj(3), shim s(1), chang s(1), chung hj(1), kim
dk(4), park y(1), lee y(2).

author information: 
(1)vaccines division, national institute food drug safety evaluation, 187 
osongsaengmyeoung 2-ro, osong-eup, heungdoek-gu, cheongju-si, chungcheongbuk-do, 
28159, republic korea.
(2)department biochemistry, college natural sciences, chungbuk national
university, cheongju-si, chungcheongbuk-do, 28644, republic korea.
(3)vaccines division, national institute food drug safety evaluation, 187 
osongsaengmyeoung 2-ro, osong-eup, heungdoek-gu, cheongju-si, chungcheongbuk-do, 
28159, republic korea. audrihojung@hanmail.net.
(4)biologics division, national institute food drug safety evaluation, 187
osongsaengmyeoung 2-ro, osong-eup, heungdoek-gu, cheongju-si, chungcheongbuk-do, 
28159, republic korea.

objectives: single radial immunodiffusion (srid) assay, used quantify
hemagglutinin (ha) influenza vaccines, requires reference reagents; however,
because centralized production reference reagents may slow emergency
deployment vaccines, alternatives needed.
results: investigated production ha proteins using recombinant dna
technology, rather traditional egg-based production process. ha
proteins used srid assay reference antigen. found ha
can quantified egg-based cell-based influenza vaccines when
recombinant (rhas) used reference antigen. furthermore, we
confirmed rhas obtained strains pandemic potential, h5n1, 
h7n3, h7n9, h9n2 strains, utilized srid assay. rha
production process takes one month, contrast traditional process
that takes three four months.
conclusions: use rhas may reduce time required produce reference
reagents facilitate timely introduction vaccines emergencies.

doi: 10.1007/s10529-017-2372-8 
pmid: 28612264  [indexed medline]

